End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
27.34 CNY | -1.90% | -0.58% | -15.20% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-15.20% | 750M | - | ||
+40.09% | 6.16B | B- | ||
-16.34% | 4.46B | C+ | ||
-7.11% | 3.27B | B- | ||
+5.14% | 3.2B | C | ||
-0.18% | 2.6B | - | D+ | |
+47.93% | 1.98B | - | ||
-7.15% | 1.7B | - | - | |
+0.67% | 1.66B | - | - | |
-8.73% | 1.61B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 603896 Stock
- Ratings Zhejiang Shouxiangu Pharmaceutical Co., Ltd.